Skip to main content
. Author manuscript; available in PMC: 2023 Mar 6.
Published in final edited form as: Leukemia. 2022 May 26;36(8):1969–1979. doi: 10.1038/s41375-022-01601-5

Figure 1. CXCR4 pathway activity discriminates human AML patients with a transcriptional signature enriched in DNA damage, oxidative stress and metabolic reprogramming.

Figure 1

(A) Gene Ontology (GO) enrichment analysis showing the top twenty most upregulated and downregulated pathways in leukemic cells with low CXCR4 pathway activation from the TARGET dataset. (B) Volcano plot showing the differentially expressed genes (adjusted p<0.05, |log2FC|>1) in leukemic cells with low CXCR4 pathway activation from the TARGET dataset. (C)Gene set enrichment analysis (GSEA) of the transcriptional signature of leukemic cells showing a deficiency in signatures related with cell adhesion and migration, as well as, an enrichment of pathways related to cell cycle, DNA damage and repair and mitochondrial respiration in patients with low CXCR4 pathway activation from theTARGET dataset.